The future of the global human microbiome market looks promising with opportunities in therapeutic and diagnostic markets.
- Within the product category, probiotics is expected to witness the highest growth over the forecast period due to the increasing consumer preference for preventive health solutions.
- Within the application category, therapeutics is expected to witness higher growth over the forecast period due to the growing research on microbiome-based disease treatments.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding healthcare investments and rising awareness levels.
Emerging Trends in Human Microbiome Market
The human microbiome market is evolving from exploratory research to clinically substantiated diagnostics, therapeutics, and nutritional products from 2025 to 2027. According to Lucintel, the market is shifting toward better-defined outcomes and more standardized manufacturing processes. Additionally, in the biotech space, there will be a higher emphasis on collaboration between biotech and healthcare providers.- Precision Therapeutics: For 2025, there will be greater focus on safer, better characterized, and more reproducible products, as compared to the use of fecal bulk in broad consortia, which has been the focus of much of the past research. Evidence beyond the first demonstration of efficacy will become the norm.
- Microbiome Diagnostics: Sequencing firms are transitioning from research panels to diagnostics that assess risk of disease and predict treatment response. Some of these tests analyze thousands of microbial features. Over the next 3-5 years, the primary barriers to market will be clinical utility and reimbursement rather than speed of sequencing.
- Evidence-led Nutrition: In the 2025-2027 time frame, brands will shift from making broad claims for probiotics to claims supported by evidence for strain benefits, or synbiotic formulations, or relationships to digestive or metabolic health. The market will expand, but requirements for clinical evidence will distinguish clinically supported products from low-cost, commoditized nutritional supplements.
- Standardized Manufacturing: There has been increasing investment in anaerobic processing, cryopreservation and controls, because exposure to oxygen can damage sensitive organisms. Improvements in manufacturing consistency will improve batch-to-batch consistency and the scalability of live biotherapeutic products over the next five years.
- Data-enabled Personalization: There will be an increasing number of clinical studies integrating microbiome data with other omics and patient data. Artificial intelligence will be used to analyze patient data to classified responders. Rather than one-time testing, personalization will shift the market to offer diagnostics to select the right patient for a treatment and to monitor the patient for response.
Recent Developments in the Human Microbiome Market
The human microbiome market is transitioning from discovery-based research to more clinically-based research for therapeutics, diagnostics, and personalized nutrition. Lucintel expects this transition to continue through the 2025 to 2027 time frame, driven by regulatory pathway clarification, venture funding, and Big Pharma interest in Microbiome assets.- Late Stage Therapeutic Financing: Assembly Biosciences raised $155 million in a private placement (January 2025) for their microbiome programs focused on various gastrointestinal and other immune-mediated conditions. Large financings will continue to help fund microbiome programs, but will pressure developers to increasingly distinguish their candidates from conventional biologics.
- Strategic Pharmaceutical Partnerships: Vedanta Biosciences' partnership with Bristol Myers Squibb is worth more than $1 billion (2025). Partnerships such as these give smaller companies the ability to out-source clinical trial infrastructure. Additionally, these partnerships provide investors with data that validates the mechanisms of the microbiome.
- Manufacturing Scale-up: In 2025, the former assets of 4D pharma along with related programs of live biotherapeutics, continued their development towards the establishment of a GMP (good manufacturing practice) production. Starting in 2025, commercial supply will rely on the reproducibility of potency, and Quality Controls of strains rather than Lab-in-Vitro evidence.
- Diagnostic Platform Expansion: The microbiome testing companies expanded their diagnostic offerings in 2025, enabling them to sequence over 1,000 microbial taxa. As resolution improves, microbiome testing is being integrated for companion diagnostics for cancer, and to aid in the diagnosis of inflammatory disorders.
- Regulatory Pathway Development: 2025 marked the second year of the application of lessons learned from the two only microbiota-based products approved by the FDA, Vow and Rebyota. Greater donor screening and better consistency in manufacturing will encourage more submissions of live biotherapeutics.
Strategic Growth Opportunities in the Human Microbiome Market
Between 2024 and 2026, there will be growing interest in developing validated products from the microbiome field, as opposed to projects focused on research and discovery in the microbiome. Lucintel identifies strong market opportunities in therapeutics, diagnostics, nutrition, and animal health. Faster and better sequencing, regulatory guidance, biobanks, and venture funding shorten product development cycles. Additionally, the healthcare system emphasizes prevention and targeted treatment.- Microbiome Therapeutics: There are numerous live biotherapeutic products (including probiotics, postbiotics, and synbiotics) in development to address recurrent/chronic infection and inflammation, as well as to provide immune-oncology support and other indications. According to January 2025 data, there were over 1,000 microbiome-related studies across the globe. It is anticipated that licensing, manufacturing, and companion diagnostics, among others, will emerge as revenue-generating opportunities within the next 3 to 5 years.
- Precision Nutrition: Personalized probiotics and postbiotics can create microbiome-based diet recommendations. Approximately 52% of US consumers reported in the June 2025 International Food Information Council survey that they consumed functional foods and beverages. Data-linked nutrition programs will help create recurring subscriptions and premium products.
- Microbiome Diagnostics: Faster metagenomics can help with treatment selection, assess disease-risk, and provide clinical-monitoring. In February 2025, the FDA listed more than 900 next-generation sequencing devices or assays in their regulatory database. Improving evidence and the development of reimbursement will influence adoption by hospitals and labs.
- Women’s Health: Products targeting the vaginal microbiome can assist in the diagnosis and treatment of various conditions including bacterial vaginosis and fertility care. The World Health Organization reported in April 2025, approximately 374 million new cases of curable sexually transmitted infections each year. There are opportunities to serve the specialized provider and patient markets.
- Animal Health and Agriculture: Using the microbiome to increase the performance of livestock and other agricultural products can reduce reliance on antibiotic use and other measures. In March 2025, the USDA reported that the value of the US animal agriculture output was over $250 billion. There are opportunities to help solve the problem of increasing mortality and poor feed conversion.
Human Microbiome Market Drivers and Challenges
Ongoing innovation in technology, healthcare economics, and regulations are reshaping the market. The same is true for consumer demand for individualized treatments. Rising opportunities are colliding with regulatory and reimbursement challenges, complex clinical situations, and high costs. According to Lucintel, the market is emerging for therapeutics, diagnostics, nutrition, and personalized medicine. In the coming years, the healthcare market will be shaped by clinical validation, scalable manufacturing, and other research and market-related investments.The factors responsible for driving this market include:
- Rising Demand for Personalized Medicine: There is increasing interest from both patients and healthcare professionals for individualized medicine based on biological factors including the microbiome. Microbiome analysis plays a role in patient stratification and assessment of disease risk and helps in the identification of targeted interventions for gastrointestinal, metabolic, immune and oncology disorders. The industry predicted double digit growth for microbiome testing and therapeutics in 2025 and this will positively influence the market in the next 3 to 5 years, especially the uptake of personalized medicine.
- Advances in Sequencing and Artificial Intelligence: Technological advancements such as reduced cost of next generation sequencing and omics, automation and artificial intelligence have improved the identification of microbial patterns, and functional pathways. These have aided the separation of clinically significant microbes from background variability and aided the discovery of biomarkers. Next generation sequencing platforms available in 2025 delivered results in days instead of weeks. In the next 3 to 5 years, continued improvements in automation, artificial intelligence and next generation sequencing will increase the pace and reproducibility of population research and further strengthen the market.
- The Microbiome Market is Exhibiting Significant Growth: Research has gone beyond standard probiotics to include other therapeutic products, defined microbial consortia, phages, genetically engineered bacteria, and microbiome-derived metabolites. These will allow more effective precision medicine approaches to treat a broader range of conditions that are not appropriately served by available therapeutic options. Through 2025, the worldwide clinical pipeline continued to expand and include hundreds of candidates for gastrointestinal, inflammatory, metabolic, oncologic indications, and others. The remaining candidates will drive the market in the next three to five years. Before approvals are granted, positive results will give further confidence to pharmaceutical and venture investors to introduce more partnerships and truly establish microbiome therapeutics as a pharmaceutical category.
- More Preventive Healthcare and Nutrition Opportunities: The expansion of the consumer market focused on digestive health and wellness, immunity, personalized nutrition and preventive health will translate to growth for the microbiome market. Consumers will be able to access preventive health and microbiome-related products in various forms including supplements, food, home tests, digital apps and more. In 2025, products across several consumer categories including supplements (i.e. probiotics and prebiotics), postbiotics, nutrition and other wellness products remained available. In the next three to five years, the microbiome market will largely be focused on the preventive health industry. Effective and measurable health outcomes will be strongly preferred over generally wellness and integrity claims to support product differentiation.
- Improved Manufacturing and Commercial Infrastructure: Advances in anaerobic cultivation, cryopreservation, fermentation, quality control, and supply chain management allowed manufacture of complex microbial products. Further, developers invested in closed, standardized processing and formulations. In 2025, most commercial manufacturers used controlled, scalable and automated production systems designed to minimize process contamination and variability between batches. This trend will have the most significance on the market in the next 3-5 years. Dependable manufacturing is key for the regulatory process to approve product licenses, for building physician confidence and ultimately reduce costs. Improved manufacturing should reduce the costs for clinical studies and increase the availability of microbiome products across hospitals and specialty care networks.
The challenges facing this market include:
- Clinical Variability and Limited Validation: Microbiome varies across population based on diet, geography, age, genetics, medications, and lifestyle, making them difficult to reproduce. Many studies remain small, observational, and inconsistent in their definition of a healthy/unhealthy microbial community. In 2025, researchers reemphasized the importance of large multicenter studies and consistent standardized sampling procedures. They noted that variations between studies remain, and these challenges will impact the market in the next 3-5 years by delaying adoption of diagnostic products and increasing the cost of R&D. Companies should develop products which provide clinical meaningful outcomes and validate their biomarkers.
- Regulatory and Reimbursement Challenges: Uncertainty exists for microbiome products concerning evidence and standards for manufacturing, labeling, and post-market experience. In 2025, developers reported continuing to adapt to variation in regulatory requirements across the U.S., Europe, and Asia, and uncertain and limited reimbursement policies. Pathway unpredictability will continue to have market impact over the next three to five years, as it delays entry of advanced products and discourages smaller companies from entering the market. Health economic evidence, standardization and harmonization of regulations and methods will facilitate broader clinical adoption.
- Cost and Complexity of Manufacturing: In 2025, challenges related to manufacturing and formulation complexity limited many microbiome product development programs to large, well-funded organizations and created high prices for those products that did reach the market. Automation, better formulations, regional manufacturing and scalable fermentation will help lower the costs of manufacturing microbiome products.
List of Human Microbiome Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies human microbiome market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the human microbiome market companies profiled in this report include:
- Enterome
- Seres Therapeutics
- 4D Pharma
- DuPont
- Vedanta Biosciences
- Osel
- Merck & Co.
Human Microbiome Market by Segment
The study includes a forecast for the global human microbiome market by product, disease type, technology, application, and region.Product [Value ($M) from 2019 to 2035]:
- Prebiotics
- Probiotics
- Food
- Medical Food
- Drugs
Disease Type [Value ($M) from 2019 to 2035]:
- Infectious
- Metabolic/ Endocrine
- Cancer
- Blood
- Neurological
Technology [Value ($M) from 2019 to 2035]:
- Proteomics
- Metabolomics
- Genomics
Application [Value ($M) from 2019 to 2035]:
- Therapeutics
- Diagnostics
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Human Microbiome Market
The human microbiome market has experienced rapid growth driven by advances in biotechnology, increasing awareness of microbiome health, and expanding applications in personalized medicine, diagnostics, and therapeutics. As research uncovers the microbiome's role in various health conditions, countries are investing heavily in innovation, regulatory frameworks, and collaborations to capitalize on this emerging field. The market's evolution reflects a global shift towards microbiome-based solutions for disease prevention and treatment, with key players focusing on product development, clinical trials, and commercialization strategies. This dynamic landscape is shaping the future of healthcare, emphasizing the importance of microbiome research across different regions.- United States: The US leads in microbiome research and commercialization, with significant investments from biotech firms and government agencies like NIH. Recent developments include the approval of microbiome-based therapeutics and expansion of clinical trials focusing on gastrointestinal and metabolic disorders. Major companies are forming strategic partnerships to develop personalized microbiome treatments, and regulatory agencies are working to establish clear guidelines for product approval. The US also sees increased consumer interest in microbiome testing kits, fueling market growth and innovation.
- China: China has rapidly advanced in microbiome research, supported by government initiatives and substantial funding. Recent developments include the launch of large-scale microbiome projects and the establishment of research centers dedicated to microbiome science. Chinese companies are developing microbiome-based products for digestive health and immune support, with a focus on integrating traditional medicine with modern biotechnology. The market is also witnessing increased collaborations with international firms, aiming to accelerate product development and regulatory approval processes.
- Germany: Germany remains a key player in microbiome research within Europe, with a focus on clinical applications and diagnostics. Recent advancements include the development of microbiome analysis tools and probiotic formulations for gastrointestinal health. German research institutions are actively involved in European Union-funded projects to explore microbiome's role in chronic diseases. The country emphasizes regulatory compliance and quality standards, fostering innovation in microbiome therapeutics and personalized nutrition solutions.
- India: India is emerging as a significant market for microbiome research, driven by rising awareness of gut health and increasing investment in biotech startups. Recent developments include the launch of microbiome-based diagnostic services and probiotic products tailored to local populations. The government is promoting microbiome research through funding and policy support, aiming to integrate traditional Ayurvedic practices with modern microbiome science. The market is also witnessing collaborations between academia and industry to develop affordable microbiome solutions for widespread health issues.
- Japan: Japan has a strong focus on microbiome research, particularly in aging and metabolic health. Recent advancements include the development of microbiome-targeted therapies and functional foods. Japanese companies are exploring microbiome modulation to improve health outcomes in elderly populations, with several products in clinical trials. The government supports microbiome research through funding and regulatory initiatives, fostering innovation in personalized nutrition and therapeutics. Japan's emphasis on integrating traditional dietary practices with modern science positions it as a leader in microbiome-based health solutions.
Features of the Global Human Microbiome Market
- Market Size Estimates: human microbiome market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: human microbiome market size by various segments, such as by product, disease type, technology, application, and region in terms of value ($M).
- Regional Analysis: human microbiome market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, disease type, technology, application, and regions for the human microbiome market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human microbiome market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the human microbiome market by product (prebiotics, probiotics, food, medical food, and drugs), disease type (infectious, metabolic/ endocrine, cancer, blood, and neurological), technology (proteomics, metabolomics, and genomics), application (therapeutics and diagnostics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Enterome
- Seres Therapeutics
- 4D Pharma
- DuPont
- Vedanta Biosciences
- Osel
- Merck & Co.
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

